Thursday, February 7, 2013

Biogen acquires sole rights to MS drug from Elan for $3.25B

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ejtDCduTtWCfyshnCidncVCicNFBMR

February 7, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  Health Care & Policy 
  • J&J leads ranking of most productive pharmaceutical firms
    Johnson & Johnson topped IDEA Pharma's third annual Productive Innovation Index, which seeks to rank drugmakers by their ability to launch innovative products. J&J's rank can be attributed to the commercialization of prostate cancer treatment Zytiga, or abiraterone, IDEA CEO Mike Rea said. Amgen, last year's No. 1, was second, followed by Roche. Rounding out the top 10 were Merck & Co., Sanofi, Eli Lilly & Co., Novartis, GlaxoSmithKline, Bristol-Myers Squibb and Abbott. PharmaTimes (U.K.) (2/6), PharmTech.com (2/4) LinkedInFacebookTwitterEmail this Story
  • FDA seeks ways to reward quality
    The FDA is considering developing a quality scorecard for drug manufacturers in an effort to prevent quality problems that have contributed to recent drug shortages, according to an article in Clinical Pharmacology & Therapeutics by FDA officials Janet Woodcock and Marta Wosinka. Pharmalot.com/Pharma blog (2/6) LinkedInFacebookTwitterEmail this Story
  • Biotech plans human trials of osteoarthritis drug candidate
    Metabolic Pharmaceuticals plans could take its experimental osteoarthritis drug, AOD9604, to a midstage trial after obtaining positive results from an animal study. Data from the animal trial showed that AOD9604, a small 16 amino acid peptide, promoted cartilage and joint tissue repair. "These results are exciting because they provide early-stage evidence in a rabbit model that AOD9604 may help to repair OA damaged tissue," said lead researcher Dr. Dong Rak Kwon. Australian Life Scientist (2/6) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Industry Deals 
  Food & Agriculture 
  • Australian researchers working on heat-tolerant crops
    Researchers from the University of Sydney are working to develop heat-resistant varieties of crops such as wheat, chickpeas and cotton. The researchers are identifying variations in genetic collections from other countries. "We work with countries where these crops originated, for example America for cotton, and institutions where varieties of genetic crop seeds are held," said Daniel Tan, who leads the project. The Times of India (2/3) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Calif. is state with most advanced biofuel companies
    California leads all states in the number of advanced biofuel companies, accounting for nearly 30 of the more than 80 firms operating in 27 states, according to a report from Environmental Entrepreneurs. Illinois is second with eight companies, followed by Colorado, Texas and Iowa, the study showed. By 2015, 25 new advanced biofuel plants are expected to enter service, creating more than 18,000 jobs. American City Business Journals/Sacramento, Calif. (2/6) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
I am never bored anywhere: being bored is an insult to oneself."
--Jules Renard,
French author


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information

1 comment:

Elisha Mullins said...

I just required some information and was searching on leather shoes for men, High Heels shoes, women's handbags Google for it. I visited each page that came on first page and didn’t got any relevant result then I thought to check out the second one and got your blog. This is what I wanted!